At the time of NSCLC diagnosis, approximately 20% of patients with ALK gene rearrangement already present with brain metastases, and a substantial 40% to 50% of these individuals will develop CNS metastases as their disease progresses [18,19,20,21]. This evidence concerns the gene ALK and non-small cell lung carcinoma.